Newsroom - Media

Explore our news

07.12.2022

Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe

Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrat…

28.11.2022

STADA starts work on >EUR50m project to strengthen European medicines supply

23.11.2022

Stéphane Jacqmin joins STADA from Sanofi and becomes Head of Emerging Markets

11.11.2022

STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®

20.09.2022

STADA sets standard in Specialty

By launching the first medicine authorized in the EU for treating rare kidney disease

16.09.2022

STADA and Xbrane welcome EMA positive opinion for ranibizumab biosimilar candidate Ximluci

25.08.2022

Strong in-market performance leads STADA to double-digit growth

Half-year 2022 results

18.08.2022

STADA mourns CFO Dr. Wolfgang Ollig

18.07.2022

STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy

The European Commission (EC) has granted conditional marketing authorization for Kinpeygo^®

08.07.2022

STADA Health Report 2022: Europe experiencing worsening health conditions

Self-assessed burnout rates at all-time high; stress levels have increased;
more than one in three are struggling with sleep; appreciation f…

25.06.2022

People with Parkinson’s are missing out on regular specialist advice in much of Europe

Many Parkinson’s patients across Europe are missing out on regular specialist advice on treating their condition, according to the findings …

09.06.2022

STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab

Offers a comprehensive range of presentations to the EU adalimumab
biosimilars market

20.05.2022

STADA set to expand Specialty portfolio with positive CHMP opinion on Kinpeygo orphan medicine for IgAN kidney disease

STADA has taken a significant step towards expanding its Specialty portfolio

22.04.2022

STADA brings in Berndt to further develop specialties and biosimilars offerings

Dr Christine Berndt joins STADA from June as Head of Global Development Specialties/Biosimilars

06.04.2022

Alvotech and STADA pave way to launching HUKYNDRA® (AVT02)

A citrate-free, high-concentration biosimilar to Humira® by resolving European patent dispute with AbbVie

22.03.2022

STADA’s 2021 above-market development strengthens base for further growth, especially in Consumer Healthcare and Specialty

Full-year results 2021

18.03.2022

Ignis Therapeutics and STADA partner for apomorphine subcutaneous injection in China

Ignis and STADA’s Britannia sign exclusive licensing agreement to develop and commercialize subcutaneous apomorphine in mainland China, Hong…

19.01.2022

STADA expands production network with EUR50m project in Romania

STADA is preparing to meet demand for its expanding portfolio by investing almost EUR50 million in a supply-chain hub in Turda, Romania

05.01.2022

STADA sets up for success with Erin Federman as global biosimilars commercial head

Experienced expert Erin Federman will oversee commercialization of STADA’s biosimilars portfolio and pipeline

26.08.2021

STADA continues to outpace the market in H1 and strengthens basis for further growth

Half-year results 2021

View more news

STADA Health Report 2022

Europe, early summer 2021: Covid vaccination programmes across Europe were in full flow, bringing the prospect of returning to life more like we knew it before the pandemic. But had the virus changed the way we lived irreversibly? By asking detailed questions of 30,000 people across 15 countries, the STADA Health Report 2021 brought to light the immediate short-term effects of the pandemic on the lives of Europeans.

One year later, STADA checked in with Europeans to learn what longer-term effects the pandemic has left on Europe’s health landscape: How is their mental health holding up? What is worrying them? All the answers can be found in the STADA Health Report 2022